ConductScience.org, home

Comparison · NCT06115681-deaths

DDLPS Patients With 1L Treatment at Index Date (Cohort 1) vs DDLPS Patients Without 1L Treatment at Index Date (Cohort 2): deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. DDLPS Patients With 1L Treatment at Index Date (Cohort 1) vs DDLPS Patients Without 1L Treatment at Index Date (Cohort 2): deaths from any cause. Trial comparisons, record NCT06115681-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06115681-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.6360.5780.691wilson
Risk in group 20.3820.3540.411wilson
Risk difference, group 1 minus group 20.2540.1890.315newcombe hybrid score
Risk ratio, group 1 over group 21.661.481.87log
Odds ratio, group 1 over group 22.832.153.72log
Number needed to harm, for one more death from any cause on DDLPS Patients With 1L Treatment at Index Date (Cohort 1) than on DDLPS Patients Without 1L Treatment at Index Date (Cohort 2)3.943.175.3from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1DDLPS Patients With 1L Treatment at Index Date (Cohort 1)
Patients with unresectable locally advanced or metastatic differentiated liposarcoma (DDLPS) who received at least one line of systemic antineoplastic treatment by the end of cohort identification period (index date = start date of first line (1L) treatment).
175275EG000
Group 2DDLPS Patients Without 1L Treatment at Index Date (Cohort 2)
Patients with DDLPS who have not initiated 1L systemic antineoplastic treatment by the end of cohort identification period (index date = date of initial DDLPS diagnosis during cohort identification period). Patients initiated 1L treatment afterwards or patients received adjuvant and/or neoadjuvant therapy only through follow-up will be included in Cohort 2.
4231,106EG001

Harm

What it counts
Total, all-cause mortality
Time frame

Source ClinicalTrials.gov

Trial

Title
Real-world Study of Dedifferentiated Liposarcoma Patients in China
NCT number
NCT06115681
Phases
Conditions
Dedifferentiated Liposarcoma
Interventions
Lead sponsor
Boehringer Ingelheim
Results first posted
2025-07-10

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT06115681-deaths